The role of innate immune signals in antitumor immunity

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 189-194

  Jinushi, Masahisa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antitumor immunity; Immunotheropy; NOD like receptors; RIG I like helicase; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CRYOPYRIN; HELICASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN AIM2; RETINOIC ACID INDUCIBLE PROTEIN I; RIG I LIKE HELICASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOKINE RELEASE; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 84862704935     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18495     Document Type: Review

References (57)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20; http://dx.doi.org/10.1016/j.cell.2010.01.022
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84; http://dx.doi.org/10.1038/ni.1863
3. Watts C, West MA, Zaru R. TLR signaling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010; 22:124-30; http://dx.doi.org/10.1016/j.coi.2009.12.005
4. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5; http://dx.doi.org/10.1126/science.1183021
5. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008; 99:467-78; http://dx.doi.org/10.1111/j.1349-7006.2007.00720.x
6. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; http://dx.doi.org/10.1016/j.immuni.2004.07.017
7. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9; http://dx.doi.org/10.1038/ni1213
8. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signaling to p53 responses in tumor suppression and antiviral defense. Nature 2003; 424:516-23; http://dx.doi.org/10.1038/nature01850
9. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808-12; http://dx.doi.org/10.1038/nature04596
10. Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen presentation. Nat Immunol 2006; 7:1029-35; http://dx.doi.org/10.1038/ni1006-1029
11. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4 +regulatory T cell function. Science 2005; 309:1380-84
12. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27:334-48; http://dx.doi.org/10.1016/j.immuni.2007.05.020
13. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7-MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200; http://dx.doi.org/10.1038/ni758
14. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequencespecific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70; http://dx.doi.org/10.1038/nm1191
15. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-51; http://dx.doi.org/10.1084/jem.20070021
16. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184-94; http://dx.doi.org/10.1172/JCI31414
17. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, von Bubnoff D, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36: 12-20; http://dx.doi.org/10.1002/eji.200535602
18. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. CpG oligonucleotides induce splenic CD19+dendritic cells to acquire potent idolamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2006; 175:5601-5.
19. Moseman EA, Liang X, Dawson AJ, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, et al. Human plasmacytoid dendritic cells activated by CpG oligonucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173:4433-42
20. Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A, et al. Phase II trial of toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24:5716-24; http://dx.doi.org/10.1200/JCO.2006.07.9129
21. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, et al. Radomized phase II trial of a toll-like receptor 9 agonist oligonucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small cell lung cancer. J Clin Oncol 2008; 26:3979-86; http://dx.doi.org/10.1200/JCO.2007.12.5807
22. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117:2197-204; http://dx.doi.org/10.1172/JCI32205
23. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; http://dx.doi.org/10.1038/nm1622
24. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; http://dx.doi.org/10.1172/JCI35180
25. Miyake T, Kumagai Y, Kato H, Guo Z, Matsushita K, Satoh T, et al. Poly I:C-induced activation of Nk cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIFdependent pathways. J Immunol 2009; 183:2522-8; http://dx.doi.org/10.4049/jimmunol.0901500
26. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of MDA5 and TLR3 in poly (I:C)-mediated activation of NK cells. J Exp Med 2009; 206:2967-76; http://dx.doi.org/10.1084/jem. 20091181
27. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, et al. Antitumor NK activation induced by the toll-like receptor 3-TICAM (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007; 104:252-7; http://dx.doi.org/10.1073/pnas.0605978104
28. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176:4894-901
29. Besch R, Poeck H, Hohenauer T, Hohenauer T, Senft D, Hacker G, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonindependent apoptosis in human melanoma cells. J Clin Invest 2009; 119:2399-411
30. Kübler K, Gehrke N, Riemann S, Bohnert V, Zillinger T, Hartmann E, et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010; 70:5293-304; http://dx.doi.org/10.1158/0008-5472.CAN-10-0825
31. Poeck H, Besch R, Maihoefer C, Maihoefer C, Renn M, Tormo D, et al. 5'-Triphosphate-siRNA turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14:1256-63; http://dx.doi.org/10.1038/nm.1887
32. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol 2010; 184: 939-46; http://dx.doi.org/10.4049/jimmunol.0901245
33. Pan M, Geng S, Xiao S, Ren J, Liu Y, Li X, et al. Apoptosis induced by synthetic retinoic acid CD437 on human melanoma A375 cells involves RIG-I pathway. Arch Dermatol Res 2009; 301:15-20; http://dx.doi.org/10.1007/s00403-008-0902-x
34. Ting JP, Duncan JA, Lei Y. How the non-inflammasome NLRs function in the innate immune system? Science 2010; 327:286-90; http://dx.doi.org/10.1126/science.1184004
35. Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009; 4:365-98; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092239
36. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6; http://dx.doi.org/10.1038/35079114
37. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezaed JP, Belaiche J, et al. Association of NOD2 leucin-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603; http://dx.doi.org/10.1038/35079107
38. da Silva Correia J, Miranda YY, Austin-Brown N, Hsu J, Mathison J, Xiang R, et al. Nod1-dependent control of tumor growth. Proc Natl Acad Sci USA 2006; 103:1840-5; http://dx.doi.org/10.1073/pnas.0509228103
39. Chen GY, Shaw MH, Redondo G, Nunez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 2008; 68:10060-7; http://dx.doi.org/10.1158/0008-5472.CAN-08-2061
40. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41; http://dx.doi.org/10.1038/nature04516
41. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327:296-300; http://dx.doi.org/10.1126/science.1184003
42. Schroder K, Tshopp J. The inflammasome. Cell 2010; 140:821-32; http://dx.doi.org/10.1016/j.cell.2010.01.040
43. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045-56; http://dx.doi.org/10.1084/jem.20100050
44. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SG, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282-6; http://dx.doi.org/10.1038/nature08296
45. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11:136-40; http://dx.doi.org/10.1038/ni.1831
46. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; http://dx.doi.org/10.1038/nm.2028
47. Faustin B, Chen Y, Zhai D, Negrate GL, Lartigue L, Satterthwait A, et al. Mechanisms of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: loop domaindependent suppression of ATP binding and oligomerization. Proc Natl Acad Sci USA 2009; 106:3935-40; http://dx.doi.org/10.1073/pnas.0809414106
48. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of Autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456:264-8; http://dx.doi.org/10.1038/nature07383
49. Bürckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, et al. An orthogonal proteomicgenomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10:266-72; http://dx.doi.org/10. 1038/ni.1702
50. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509-13; http://dx.doi.org/10.1038/nature07710
51. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-8; http://dx.doi.org/10.1038/nature07725
52. Roberts TL, Idris A, Kelly JA, Burnton CM, Hodgson S, Hardy LL, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60; http://dx.doi.org/10.1126/science.1169841
53. DeYoung KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997; 15:453-7; http://dx. doi.org/10.1038/sj.onc.1201206
54. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7:99-109; http://dx.doi.org/10.1038/nrmicro2070
55. Patsps G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2009; 126:1838-49.
56. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; http://dx.doi.org/10.1038/nature01322
57. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; http://dx.doi.org/10.1016/j.cell.2010. 01.025